Redeye gives its initial take on Xvivo’s Q3 report. Sales came in line, with a cosmetic positive deviation. EBITDA beat consensus by c20% albeit in relatively low absolute figures. Considering the challenging times the share has faced, we emphasise that a relatively neutral report is a strong positive at this point, allowing the company to regain investor confidence. We expect the share to react slightly positively today (c3-5%).
LÄS MER
